Novo Nordisk acquires Akero Therapeutics for up to $5.2 billion for a promising liver disease drug candidate. CEO Mike Doustdar focuses on effective obesity and diabetes drugs like efruxifermin for MASH. Novo aims to combat market share losses and prepare for semaglutide’s loss of exclusivity.

Efruxifermin shows potential in reversing liver scarring in MASH patients. Doustdar sees it as crucial for future growth amid upcoming challenges. Novo’s move to acquire Akero reflects a strategic expansion in a high-growth area, following recent industry trends by competitors like Roche and GSK.

Novo’s deal with Akero is a significant step in expanding its pipeline, with a focus on metabolic diseases. Shareholder Lukas Leu praises the move but remains cautious due to Novo’s stock performance. The deal includes an upfront cash payment and additional payments upon efruxifermin’s U.S. approval.

Novo’s shares have risen since Doustdar’s appointment, but concerns linger over Wegovy’s U.S. prescription trends. The Akero deal includes a premium over Akero’s last closing price and additional payments contingent on efruxifermin’s success. Novo aims to strengthen its position in the market through strategic acquisitions and growth initiatives.

Read more at Yahoo Finance: Novo to buy Akero for up to $5.2 billion in new CEO’s revival push